SEC Filings

Filing Date Form Description
July 19, 2021 6-K Biophytis announces a Judgment rendered on July 16, 2021 in the proceedings between Biophytis and Negma Group Ltd by the Execution Judge from the Paris Court of Justice PDF
July 8, 2021 6-K Biophytis announces the Reinforcement of Leadership Teams with Three Senior Appointments PDF
June 30, 2021 6-K Biophytis announces that the results of SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be released by August 2021 PDF
June 30, 2021 6-K Biophytis announces that it will secure the manufacturing of Sarconeos (BIO101) for COVID-19 with a global CDMO and the next milestones for the COVA Phase 2-3 study PDF
June 18, 2021 6-K Biophytis announces new convertible bonds financing upt to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million PDF
May 12, 2021 6-K Biophytis Completed the Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis PDF
May 11, 2021 6-K Results of the Combined General Meeting on May 10, 2021 PDF
April 30, 2021 6-K Biophytis Second Combined General Meeting to take place on May 10, 2021 without the physical presence of its shareholers PDF
April 29, 2021 6-K Biophytis Receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD PDF
April 27, 2021 6-K Convening of another Combined General Meeting at a later date PDF
April 26, 2021 6-K Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021 PDF
March 22, 2021 6-K Biophytis gives update on its Phase 2-3 COVA study on COVID-19 PDF
March 19, 2021 6-K Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd PDF
March 12, 2021 6-K Annual General Meeting will take place on April 26, 2021 PDF
March 11, 2021 20-F Annual Report for the Fiscal Year Ended Dec 31, 2020 PDF
Feb 26, 2021 6-K Biophytis Reports 2020 Full Year Results PDF
Feb 17, 2021 6-K Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial PDF
Feb 16, 2021 6-K Report of Foreign Private Issuer PDF
Feb 9, 2021 Final Prospectus PDF
Feb 9, 2021 F-1 Amendment No 3 PDF
Feb 8, 2021 FWP Free Writing Prospectus PDF
Feb 4, 2021 F-8A For Registration of Certain Classes of Securities Pursuant to Section 12(b) or (g) PDF
Feb 4, 2021 F-1 Amendment No 2 PDF
Feb 2, 2021 FWP Free Writing Prospectus PDF
Feb 2, 2021 F-1 Amendment No 1 PDF
Jan 19, 2021 F-1 Form F-1 PDF
Dec 23, 2020 F-1 Draft Registration Statement PDF
Nov 20, 2020 F-1 Draft Registration Statement PDF